According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.
GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. With this data in hand, Iveric Bio is working to submit a New Drug Application for Zimura to the FDA by the end of the first quarter of next year.
Surveys have found that burnout among physicians who deliver “primary care” is so bad that 20% of them intend to stop practicing.
Researchers have found that social media use among physicians jumped during the COVID-19 pandemic, but the role it plays in networking, mentorship and support among ophthalmologists remains unknown.
According to the company, the fully connected environment, digital technologies and artificial intelligence tools enable optimization of patient care.
Bausch + Lomb expects to begin the distribution of the intraocular dyes in all EU countries, with the exception of Italy, during the first half of 2023. Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets.
David J. Calkins, PhD, is being recognized for his groundbreaking contributions to the field of vision research.
The multi-center, international clinical study is designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia.
Product is forging a future in ocular regenerative procedures
Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.
The debate continues about the protective effect of eyeglasses against contracting the COVID-19 virus. Researchers from Denmark reported that their results were inconclusive regarding whether wearing eyeglasses is linked with a decreased risk of COVID-19 infections.
The company has filed an ophthalmic IND submission for the first treatment of ocular conditions associated with DNA damage.
On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Tocilizumab and the influence it can have on ophthalmic outcomes in giant cell arteritis.
AB 2236, which would reduce the medical education, clinical, and surgical training requirements to become licensed in California to perform eye surgery. Trade organizations and other groups are stepping up to oppose the measure.
Edward J. Holland, MD, discusses how postoperative dry eye disease after refractive and cataract procedures may lead to patient dissatisfaction.
Reducing incidents can reduces cases of infection, transmission among physicians, clinicians.
When paired with SD-OCT, the device also can be used to evaluate photoreceptors.
This award totals $65,000 to support strategic planning implementation.
The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.
Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that is the first of its kind to directly target mitochondrial function in cells that are malfunctioning in AMD.
Gene therapy has partly restored the function of the retina’s cone receptors in two children who were born completely colorblind, reports a new study led by UCL researchers.
Stoke Therapeutics announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy.
Sight Sciences Inc. is taking the wraps off Sion, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
According to investigators, the progression of myopia in children may be slowed by a metabolite of caffeine, known as 7-MX.
Alcon and Aerie Pharmaceuticals Inc. have announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie.
George Waring IV, MD, FACS, points out that supplementation and customized procedures are in the offing.
A test to detect and quantify TDP-43 deposits in the retina provides this capability for the first time and can be performed using commercially available and widely utilized diagnostic cameras.
According to researchers, functional assessments and education are critical to an early diagnosis.
